欧盟 - 荷兰文 - EMA (European Medicines Agency)

ceva santé animale - geïnactiveerd coxiella burnetii-vaccin, stam nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

欧盟 - 荷兰文 - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - varkens - voor actieve immunisatie van varkens vanaf de leeftijd van 7 weken om sterfte te voorkomen en infectie en ziekten veroorzaakt door het klassieke varkenspestvirus (csfv) te verminderen. onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.

欧盟 - 荷兰文 - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - varkens - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

欧盟 - 荷兰文 - EMA (European Medicines Agency)

intervet international bv - bluetonguevirusvaccin, serotype 8 (geïnactiveerd) - geïnactiveerde virale vaccins, blauwtong-virus, schapen - sheep; cattle - cattle to stimulate active immunity in sheep from 6 weeks of age against bluetongue virus serotype 8 to reduce viraemia sheep to stimulate active immunity in sheep from 1 month of age against bluetongue virus serotype 8 to prevent viraemia,.

欧盟 - 荷兰文 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

欧盟 - 荷兰文 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

欧盟 - 荷兰文 - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologicals voor suidae - varkens (voor de mesterij) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

欧盟 - 荷兰文 - EMA (European Medicines Agency)

intervet international bv - clostridium perfringens type c / escherichia coli f4ab / e. coli-f4ac / e. coli f5 / e. coli-f6 / e. coli lt - immunologische - varkens - voor de passieve immunisatie van kinderen door actieve immunisatie van zeugen en gelten aan het verminderen van de mortaliteit en de klinische symptomen tijdens de eerste dagen van het leven, veroorzaakt door die escherichia coli stammen die express de adhesins f4ab (k88ab), f4ac (k88ac), f5 (k99) of f6 (987p) en veroorzaakt door clostridium perfringens type c.

荷兰 - 荷兰文 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ceva sante animale b.v. - levend verzwakt aviaire metapneumovirus subtype b, stam crr126 - lyofilisaat voor oculonasale suspensie - avian rhinotracheitis virus - kippen

欧盟 - 荷兰文 - EMA (European Medicines Agency)

intervet international b.v. - celgebonden levend recombinant kalkoenherpesvirus (stam hvt / ilt-138), dat de glycoproteïnen gd en gi van infectieus laryngotracheïtisvirus tot expressie brengt - immunologicals voor aves, levende virale vaccins - kip - voor actieve immunisatie van kuikens van één dag om mortaliteit, klinische symptomen en laesies als gevolg van infectie met aviaire infectieuze laryngotracheïtis (ilt) -virus en het marek-virus (md) -virus te verminderen.